UroGen Pharma Ltd.
UroGen Pharma Ltd., a leading biopharmaceutical company headquartered in the United States, focuses on innovative therapies for urological cancers and disorders. Founded in 2004, UroGen has made significant strides in the industry, particularly with its proprietary drug delivery technology that enhances the efficacy of existing treatments. The company’s core products include UGN-101, a novel treatment for upper tract urothelial carcinoma, and UGN-102, aimed at bladder cancer. These therapies are distinguished by their unique delivery mechanisms, which target cancer cells more effectively while minimising systemic exposure. UroGen Pharma has established a strong market position, recognised for its commitment to advancing patient care through research and development in urology. With a robust pipeline and strategic partnerships, UroGen continues to shape the future of urological treatment.
DitchCarbon Score
How does UroGen Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
UroGen Pharma Ltd.'s score of 20 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
UroGen Pharma Ltd.'s reported carbon emissions
UroGen Pharma Ltd., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the absence of data may indicate a need for further transparency in their environmental practices. As the pharmaceutical industry increasingly focuses on sustainability, UroGen Pharma may benefit from establishing clear climate commitments and measurable reduction targets to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
UroGen Pharma Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
